267 related articles for article (PubMed ID: 28590325)
1. Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015.
Spradling PR; Xing J; Rupp LB; Moorman AC; Gordon SC; Lu M; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Holmberg SD;
J Clin Gastroenterol; 2018 Aug; 52(7):641-647. PubMed ID: 28590325
[TBL] [Abstract][Full Text] [Related]
2. Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid.
Pham TT; Keast SL; Farmer KC; Thompson DM; Rathbun RC; Nesser NJ; Holderread BP; Skrepnek GH
J Manag Care Spec Pharm; 2018 Jul; 24(7):664-676. PubMed ID: 29952711
[TBL] [Abstract][Full Text] [Related]
3. Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C.
Park H; Song HJ; Jiang X; Henry L; Cook RL; Nelson DR
Hepatol Commun; 2021 Feb; 5(2):203-216. PubMed ID: 33553969
[TBL] [Abstract][Full Text] [Related]
4. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
[TBL] [Abstract][Full Text] [Related]
5. Racial/Ethnic and Socioeconomic Disparities in Use of Direct-Acting Antivirals Among Medicare Beneficiaries with Chronic Hepatitis C, 2014-2016.
Jung J; Du P; Feldman R; Kong L; Riley T
J Manag Care Spec Pharm; 2019 Nov; 25(11):1236-1242. PubMed ID: 31663464
[TBL] [Abstract][Full Text] [Related]
6. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
[TBL] [Abstract][Full Text] [Related]
7. Psychosocial Obstacles to Hepatitis C Treatment Initiation Among Patients in Care: A Hitch in the Cascade of Cure.
Spradling PR; Zhong Y; Moorman AC; Rupp LB; Lu M; Gordon SC; Teshale EH; Schmidt MA; Daida YG; Boscarino JA;
Hepatol Commun; 2021 Mar; 5(3):400-411. PubMed ID: 33681675
[TBL] [Abstract][Full Text] [Related]
8. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
Arias A; Aguilera A; Soriano V; Benítez-Gutiérrez L; Lledó G; Navarro D; Treviño A; Otero E; Peña JM; Cuervas-Mons V; de Mendoza C
Antivir Ther; 2017; 22(4):307-312. PubMed ID: 27341294
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study.
Gordon SC; Lamerato LE; Rupp LB; Holmberg SD; Moorman AC; Spradling PR; Teshale E; Xu F; Boscarino JA; Vijayadeva V; Schmidt MA; Oja-Tebbe N; Lu M
Am J Gastroenterol; 2015 Aug; 110(8):1169-77; quiz 1178. PubMed ID: 26215529
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic HCV genotype 1 coinfection.
Boesecke C; Rockstroh JK
Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
[TBL] [Abstract][Full Text] [Related]
11. Vital Signs: Hepatitis C Treatment Among Insured Adults - United States, 2019-2020.
Thompson WW; Symum H; Sandul A; ; Gupta N; Patel P; Nelson N; Mermin J; Wester C
MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(32):1011-1017. PubMed ID: 35951484
[TBL] [Abstract][Full Text] [Related]
12. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.
Socías ME; Ti L; Wood E; Nosova E; Hull M; Hayashi K; Debeck K; Milloy MJ
Liver Int; 2019 Aug; 39(8):1400-1407. PubMed ID: 30653809
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?
Zuckerman AD; Douglas A; Whelchel K; Choi L; DeClercq J; Chastain CA
PLoS One; 2019; 14(11):e0225434. PubMed ID: 31751399
[TBL] [Abstract][Full Text] [Related]
14. Treating Hepatitis C in a Ryan White-Funded HIV Clinic: Has the Treatment Uptake Improved in the Interferon-Free Directly Active Antiviral Era?
Cope R; Glowa T; Faulds S; McMahon D; Prasad R
AIDS Patient Care STDS; 2016 Feb; 30(2):51-5. PubMed ID: 26744994
[TBL] [Abstract][Full Text] [Related]
15. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study.
Béguelin C; Suter A; Bernasconi E; Fehr J; Kovari H; Bucher HC; Stoeckle M; Cavassini M; Rougemont M; Schmid P; Wandeler G; Rauch A;
Liver Int; 2018 Mar; 38(3):424-431. PubMed ID: 28741901
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
17. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
Pradat P; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
J Infect; 2017 Sep; 75(3):234-241. PubMed ID: 28579302
[TBL] [Abstract][Full Text] [Related]
18. Identifying Barriers to the Treatment of Chronic Hepatitis C Infection.
Al-Khazraji A; Patel I; Saleh M; Ashraf A; Lieber J; Malik R
Dig Dis; 2020; 38(1):46-52. PubMed ID: 31422405
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.
Andrieux-Meyer I; Tan SS; Thanprasertsuk S; Salvadori N; Menétrey C; Simon F; Cressey TR; Said HRHM; Hassan MRA; Omar H; Tee HP; Chan WK; Kumar S; Thongsawat S; Thetket K; Avihingsanon A; Khemnark S; Yerly S; Ngo-Giang-Huong N; Siva S; Swanson A; Goyal V; Bompart F; Pécoul B; Murad S
Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):448-458. PubMed ID: 33865507
[TBL] [Abstract][Full Text] [Related]
20. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]